Tag: secondary progressive multiple sclerosis

Masitinib Impresses in ‘Nonactive’ Progressive MS

The investigational drug, masitinib (AB Science), which has a completely new mechanism of action for multiple sclerosis (MS), has shown a positive result in slowing...

NfL Blood Biomarker Captures Suboptimal Treatment Response in MS

Measuring serum levels of neurofilament light chain (NfL) is an effective way of detecting disease activity and the need to optimize treatment in patients with...

Cardiovascular Risk Factors Linked to Brain Atrophy in MS

Dr Raffaello Bonacchi The presence of cardiovascular risk factors in patients with multiple sclerosis (MS) is associated with a greater degree of brain atrophy even...

FDA OKs Ofatumumab (Kesimpta) for Relapsing Forms of MS

The US Food and Drug Administration (FDA) has approved ofatumumab injection (Kesimpta, Novartis) for the treatment of adults with relapsing forms of multiple sclerosis, including...

Five-Year Siponimod Data Support Early MS Treatment

Among patients with secondary progressive multiple sclerosis (MS) who received siponimod or placebo during a double-blind trial and entered an open-label extension, those who received...